19.  INCR provides Phase I to Phase IV clinical development services to  pharmaceutical, biotechnology and medical device companies.   Materially False and Misleading  Statements Issued During the Class Period   30.  Plaintiff brings this action as a class action pursuant to Federal Rule of Civil  Procedure 23(a) and (b)(3) on behalf of a class, consisting of all persons and entities that  acquired INCR securities between May 10, 2017, and November 9, 2017, inclusive, and who  were damaged thereby (the “Class”).  Excluded from the Class are Defendants, the officers and  directors of the Company, at all relevant times, members of their immediate families and their  legal representatives, heirs, successors, or assigns, and any entity in which Defendants have or  had a controlling interest.   31.  The members of the Class are so numerous that joinder of all members is  impracticable.  Throughout the Class Period, INCR’s common stock actively traded on the  NASDAQ.  While the exact number of Class members is unknown to Plaintiff at this time and  can only be ascertained through appropriate discovery, Plaintiff believes that there are at least  hundreds or thousands of members in the proposed Class.  Millions of INCR shares were traded  publicly during the Class Period on the NASDAQ.  As of November 2, 2017, INCR had  104,344,972 shares of common stock outstanding.  Record owners and other members of the  Class may be identified from records maintained by INCR or its transfer agent and may be  notified of the pendency of this action by mail, using the form of notice similar to that  customarily used in securities class actions.   32.  Plaintiff’s claims are typical of the claims of the members of the Class as all  members of the Class are similarly affected by Defendants’ wrongful conduct in violation of  federal law that is complained of herein.      33.  Plaintiff will fairly and adequately protect the interests of the members of the  Class and has retained counsel competent and experienced in class and securities litigation.    36.  The market for INCR’s securities was open, well-developed and efficient at all  relevant times.  As a result of these materially false and/or misleading statements, and/or failures  to disclose, INCR’s securities traded at artificially inflated prices during the Class Period.   Plaintiff and other members of the Class purchased or otherwise acquired INCR’s securities  relying upon the integrity of the market price of the Company’s securities and market  information relating to INCR, and have been damaged thereby.   48.  Plaintiff repeats and re-alleges each and every allegation contained above as if  fully set forth herein.    49.  During the Class Period, Defendants carried out a plan, scheme and course of  conduct which was intended to and, throughout the Class Period, did: (i) deceive the investing  public, including Plaintiff and other Class members, as alleged herein; and (ii) cause Plaintiff and  other members of the Class to purchase INCR’s securities at artificially inflated prices.  In  furtherance of this unlawful scheme, plan and course of conduct, Defendants, and each  defendant, took the actions set forth herein.   59.  Plaintiff repeats and re-alleges each and every allegation contained above as if  fully set forth herein.    60.  Individual Defendants acted as controlling persons of INCR within the meaning  of Section 20(a) of the Exchange Act as alleged herein. By virtue of their high-level positions  and their ownership and contractual rights, participation in, and/or awareness of the Company’s  operations and intimate knowledge of the false financial statements filed by the Company with  the SEC and disseminated to the investing public, Individual Defendants had the power to  influence and control and did influence and control, directly or indirectly, the decision-making of  the Company, including the content and dissemination of the various statements which Plaintiff  contends are false and misleading. Individual Defendants were provided with or had unlimited  access to copies of the Company’s reports, press releases, public filings, and other statements  alleged by Plaintiff to be misleading prior to and/or shortly after these statements were issued  and had the ability to prevent the issuance of the statements or cause the statements to be  corrected.    61.  In particular, Individual Defendants had direct and supervisory involvement in the  day-to-day operations of the Company and, therefore, had the power to control or influence the  particular transactions giving rise to the securities violations as alleged herein, and exercised the  same.   Background   Violation of Section 10(b) of The Exchange Act and   Rule 10b-5 Promulgated Thereunder   Against All Defendants   Violation of Section 20(a) of The Exchange Act   Against the Individual Defendants  